Figures computed from official regulatory filings — .
Analysttarget 28.18 USD (+106%) · consensus 4.67/5 · 11 buy · 1 hold · 0 sell
Ownershipinsiders 2.93% · institutions 106.04% · short 24.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for 4D Molecular Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
5 buys93 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Bizily Scott | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bizily Scott | Sell | $22.3K | SEC |
| Bizily Scott | Exercise | $6.8K | SEC |
| Kirn David | Sell | $811K | SEC |
| Bizily Scott | Sell | $8.2K | SEC |
| Bizily Scott | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bizily Scott | Exercise | $3.8K | SEC |
| Kirn David | Exercise | $207K | SEC |
| Kirn David | Sell | $662.6K | SEC |
| Kirn David | Sell | $425.7K | SEC |
| Kirn David | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bizily Scott | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bizily Scott | Exercise | $6.8K | SEC |
| Bizily Scott | Sell | $19.9K | SEC |
| Bizily Scott | Exercise | $6.8K | SEC |
| Bizily Scott | Sell | $19.6K | SEC |
| Bizily Scott | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kirn David | Sell | $274.6K | SEC |
| Kirn David | Sell | $124.7K | SEC |
| Kirn David | Sell | $548.2K | SEC |
| Kirn David | Sell | $5.7K | SEC |
| Kirn David | Sell | $183.6K | SEC |
| Bizily Scott | Sell | $91.9K | SEC |
| Bizily Scott | Exercise | $3.4K | SEC |
| Bizily Scott | Exercise | $37.3K | Unusual size | SEC |